Skip to content

Regenxbio RGNX Gross margin

Gross margin at other companies

Biogen logo
BiogenBIIB
75.5%-0.1pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
76.5%-2.9pp
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
93.4%+3.7pp
Opko Health logo
Opko HealthOPK
36%+4.2pp

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Calculated from Regenxbio’s reported figures.

Based on trailing twelve months.

The official record: Regenxbio’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's gross margin?
Regenxbio (RGNX) reported gross margin of 59.7% in Q4 2024.
How has Regenxbio's gross margin changed year-over-year?
Regenxbio's gross margin increased by 1.6% year-over-year, from 58.8% to 59.7%.
What is the long-term trend for Regenxbio's gross margin?
Over 4 years (2020 to 2024), Regenxbio's gross margin has grown at a -6.1% compound annual growth rate (CAGR), from 76.9% to 59.7%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.